DOCSLIB.ORG

Manfred Donike Workshop 2020 Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Manfred Donike Workshop 2020 Table of Contents Recent Advances in Doping Analysis (28) – Proceedings of the 38th Cologne Workshop, 9.2. –14.2.2020 MANFRED DONIKE WORKSHOP 2020 TABLE OF CONTENTS PAGE LECTURES Marchand A, Ericsson M, Audran M, Fenaille F, Capdeville P, Martin L: EPO Biosimilars with unusual profiles: characterization and detection .................................... 13‐22 Heiland CE, Masquelier M: Sepharose gel beads: an effective technique for recombinant erythropoietin immuno‐ purification from blood ................................................................................................................ 23‐27 POSTER PRESENTATIONS Sigmund G, Geyer H, Goergens C, Thevis M: Prevalence of the imidazole derivatives naphazoline, oxymetazoline and xylometa‐ zoline in doping control samples ................................................................................................. 28‐31 Wicka M, Kaliszewski P, Grucza K, Stanczyk D, Drapala A, Konarski P, Zalewska Z, Siek P, Michalak D, Kwiatkowska D: Elimination profile of triamcinolone acetonide and its metabolite in human urine after multiple transdermal administrationed stimulants ........................................................... 32‐36 Barbán Duarte L, Martínez Brito D, Correa Vidal T, Montes de Oca Porto R: Trend analysis and decision making in the Havana Anti‐Doping Laboratory ............................. 37‐40 Rodriguez Fernandez A, Laffita D, López Castillo D, Terrero O, Montes de Oca R: Increase in the incidence of THC in urine samples of athletes in 2019 ....................................... 41‐45 Biasini GM, Donati F, Rutigliano L, de La Torre X, Botrè F: Proteomic analysis of biomarkers of red blood cells storage: towards the development of direct detection of autologous blood transfusion ............................................ 46‐51 Donati F, Botrè F, de La Torre X, Sian V, Biasini GM, Concetti L, Rutigliano L: Evaluation of the impact of genetic polymorphisms on basal values of human serum and urinary biomarkers: implications for anti‐doping analyses ................................................. 52‐58 RECENT ADVANCES IN DOPING ANALYSIS (28) ISBN 978-3-86884-046-9 Recent Advances in Doping Analysis (28) – Proceedings of the 38th Cologne Workshop, 9.2. –14.2.2020 PAGE Momobayashi A, Kageyama S, Okano M: Detection of homologous blood transfused erythrocytes by means of a two color fluorescence flow cytometric analysis ......................................................................................... 59‐62 Zhou X, He S, Zhang L, Shen L, He C: Administration Study of rEPOs circulated in China ................................................................................... 63‐67 He S, Zhou X, Zhang L, Shen L, He C: Troubleshooting for doping analysis of EPO ................................................................................ 68‐70 Somay Selbes Y, Onol S, Kacar T, Demirel AH, Aytekin S: Effects of protease inhibitors on stability of urine hCG and LH in doping analyses ................... 71‐73 Iannone M, Botrè F, de La Torre X: Direct and indirect detection of pseudo‐endogenous steroids in plasma .................................. 74‐79 Son J, Park JW, Lee SH: Multiple Biomarkers of Anabolic Agent Administration in Urine as Candidates for Doping Diagnosis ........................................................................................................................... 80‐84 Danila G, Pop A, Toboc A, Stan C: 7‐Keto‐DHEA – a case study .......................................................................................................... 85‐89 Geyer H, Fusshöller G, Haenelt N, Mareck U, Blatt C, Gougoulidis V, Hülsemann F, Piper T, Thevis M: The ratio 5aAdiol/E as indicator for the detection of testosterone doping in athletes with naturally low T/E – a case study .......................................................................................... 90‐93 Wen C, Liu X, Tianshuo Z, Jingzhu W: Isolation of boldenone and its metabolite in urine sample and further determination of the C/ C ratios by gas chromatographycombustion‐isotope ratio mass spectrometry ............. 94‐97 Mabusa I, Du Preez H, van der Merwe T: Proposed suppression of phentermine derivatization by concomitant medication: A GC‐MS case study and suggested solution ............................................................................. 98‐102 Kaewklum M, Kaewklum S, Dithayam S, Wilairat P, Kongpatanakul S: Separation and identification of regioisomers of fluoroamphetamine and fluorometh‐ amphetamine in doping control by gas chromatography‐mass spectrometry ...................... 103‐107 Stacchini C, Dima AP, de La Torre X, Mazzarino M, Botrè F: In vitro studies of the metabolic profile of different classes of SARMs using liquid chromatographic‐mass spectrometric techniques .................................................................. 108‐112 Songsaeng R, Saardpun N, Kusamran T, Kongpatanakul S: Method Development for Identification of Growth Hormone Releasing Peptides (GHRPs) in Doping Control by UFLC/MS‐IT‐TOF ....................................................................... 113‐117 RECENT ADVANCES IN DOPING ANALYSIS (28) ISBN 978-3-86884-046-9 Recent Advances in Doping Analysis (28) – Proceedings of the 38th Cologne Workshop, 9.2. –14.2.2020 PAGE Ahi S, Dubey S, Bhardwaj A, Sahu PL: Fast and sensitive detection of small peptides in human urine using liquid chroma‐ tography tandem mass spectrometry .............................................................................................. 118‐123 Berghes B, Radu M, Cristea CD, Toboc A, Stan C: Validation of HIF activating agents confirmation methods ......................................................... 124‐128 Grucza K, Wicka M, Drapala A, Konarski P, Stanczyk D, Michalak D, Kaliszewski P, Kwiatkowska D: Impact of various purity grades of acetonitrile and different mass spectrometry ionization methods on limits of detection of dopingsubstances by means of the “Dilute‐and‐Shoot” approach ............................................................................................................ 129‐133 Alechaga E, Terrero A, Monfort N, Ventura R: UHPLC‐HRMS multi‐screening method for doping control analyses in urine samples ........... 134‐138 de la Cal A, Espinosa P, Blázquez I, Fernández B, García L, de Pedraza L, Carreras D, Muñoz G: Solving problems with HILIC columns: Compounds with difficult chromatographic behavior ................................................................................................................................................ 139‐143 Fernández‐Álvarez M, Cuervo D, Baltazar‐Martins JG, Plata MDM, Muñoz‐Guerra JA, Lara B, Del Coso J, Muñoz G, Carreras D: Determination of tramadol and its metabolites in plasma by using liquid chroma‐ tography quadrupole time‐of‐flight mass spectrometry (LC‐Q‐TOF/MS) ................................. 144‐148 Cuervo D, Fernández‐Álvarez M, Baltazar‐Martins JG, Plata MDM, Muñoz‐Guerra JA, Lara B, Del Coso J, Muñoz G, Carreras D: Determination of tramadol and its metabolites in urine via accuratemass quadrupole time‐of‐flight (Q‐TOF) LC/MS ............................................................................................................ 149‐152 PRESENTATIONS ABSTRACTS ‐ LECTURES Gotzmann A: "Operation Aderlass”: Legislation as a cornerstone of anti‐doping .............................................. 153 Rossi F, Saugy M: Dried Blood Spots: Alternative matrix to deter and detect Tramadol abuse in road cycling competitions ........................................................................................................................ 154 Knoop A, Planitz P, Wuest B, Thevis M: Evaluation of cobalt in doping control samples: Discrimination of different cobalt sources .............................................................................................................................................. 155 Paßreiter A, Thomas A, Walpurgis K, Thevis M: First steps towards uncovering gene doping with CRISPR/Cas9 .................................................... 156 RECENT ADVANCES IN DOPING ANALYSIS (28) ISBN 978-3-86884-046-9 Recent Advances in Doping Analysis (28) – Proceedings of the 38th Cologne Workshop, 9.2. –14.2.2020 PAGE Coll S, Monfort N, Alechaga &, Matabosch X, Pérez‐Mañà C, Ventura R: Evaluation of the reporting level to detect betamethasone misuse in sports: additional studies after intranasal and intramuscular administrations ........................................ 157 Walpurgis K, Rubio A, Wagener F, Krug O, Knoop A, Görgens C, Guddat S, Thevis M: Elimination profiles of microdosed ostarine mimicking contaminated products ingestion .................................................................................................................................... 158‐159 Garzinsky A, Thomas A, Krug O, Thevis M: Exhaled breath in doping controls: characterization of SensAbues® sampling devices using an aerosol test generator ....................................................................................................... 160 Mongongu C, Ericsson M, Madi Moussa E, Audran M, Coudoré F, Marchand A, Buisson C: Quantitative determination of IGF‐I in dried blood using Volumetric Absorptive Micro‐sampling and Top‐down analysis with LC‐HRMS .......................................................... 161‐162 Miller G, Madrigal K, Lamm J, Husk J, Eichner D: Detecting growth hormone abuse in dried capillary blood spots: results from a large‐ scale field trial and a controlled administration study
Load more

Recommended publications
  • Relation Between Exercise Performance and Blood Storage Condition and Storage Time in Autologous Blood Doping
    biology Review Relation between Exercise Performance and Blood Storage Condition and Storage Time in Autologous Blood Doping Benedikt Seeger and Marijke Grau * Molecular and Cellular Sports Medicine, German Sport University Cologne, 50677 Cologne, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-221-4982-6116 Simple Summary: Autologous blood doping (ABD) refers to sampling, storage, and re-infusion of one’s own blood to improve circulating red blood cell (RBC) mass and thus the oxygen transport and finally the performance capacity. This illegal technique employed by some athletes is still difficult to detect. Hence knowledge of the main effects of ABD is needed to develop valid detection methods. Performance enhancement related to ABD seems to be well documented in the literature, but applied study designs might affect the outcome that was analyzed herein. The majority of recent studies investigated the effect of cold blood storage at 4 ◦C, and only few studies focused on cryopreservation, although it might be suspected that cryopreservation is above all applied in sport. The storage duration—the time between blood sampling and re-infusion—varied in the reported literature. In most studies, storage duration might be too short to fully restore the RBC mass. It is thus concluded that most reported studies did not display common practice and that the reported performance outcome might be affected by these two variables. Thus, knowledge of the real effects of ABD, as applied in sport, on performance and associated parameters are needed to develop reliable detection techniques. Abstract: Professional athletes are expected to continuously improve their performance, and some might also use illegal methods—e.g., autologous blood doping (ABD)—to achieve improvements.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 33/16 (2006.01) A61K 31/7048 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 33/14 (2006.01) A61K 31/70 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, A61K 33/18 (2006.01) A61K 31/4196 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (21) International Application Number: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, PCT/US20 13/030788 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (22) International Filing Date: ZM, ZW. 13 March 2013 (13.03.2013) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/612,689 19 March 2012 (19.03.2012) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Avenue, New Haven, CT 065 10 (US).
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT NAME DHEA (Prasterone) (Micronized) PRODUCT CODE 0733 SUPPLIER MEDISCA Inc. Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 USES Adjuvant; Androgen SECTION 2: HAZARDS IDENTIFICATION GHS CLASSIFICATION Toxic to Reproduction (Category 2) PICTOGRAM SIGNAL WORD Warning HAZARD STATEMENT(S) Reproductive effector, prohormone. Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. Causes serious eye irritation. Causes skin and respiratory irritation. Very toxic to aquatic life with long lasting effects. AUSTRALIA-ONLY HAZARDS Not Applicable. PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dusts or mists. Do not eat, drink or smoke when using this product. Avoid contact during pregnancy/while nursing. Wear protective gloves, protective clothing, eye protection, face protection. Avoid release to the environment. Response IF ON SKIN (HAIR): Wash with plenty of water.
    [Show full text]
  • Download (PDF 277.63
    PROJECT REVIEW “Characterization of the main metabolites of 17-methylstenblone and 17 methylmethenolone produced by human hepatocytes and liver fractions” Prof C. Ayotte, (INRS-Institut Armand-Frappier, Canada) New steroids openly appear on the market in products labelled with a rather confusing nomenclature. Once characterized, pharmaceutical grade products not being available, knowledge of the biotransformation pathways essential to an efficient detection of utilization by athletes is difficult to gain since administration to human volunteers should be restricted to the minimum. The alternative is a reliable in vitro model. Human hepatocytes, fresh or cryopreserved are now available commercially. We have successfully produced and identified phase I metabolites from incubations of human hepatocytes with different steroids, such as 17-methyldrostanolone and desoxymethyltestosterone (DMT). The aim of this project is to produce in vitro from human hepatocytes and liver fractions the metabolites of two steroids, the 17-methylated derivatives of stenbolone and its isomer methenolone. The principal metabolites will be synthesized and characterized by NMR and mass spectrometry. The characterization of metabolites will enable the identification of markers of utilization to be incorporated in routine testing methods. The approach for the chemical synthesis of metabolites will be shared with NMI insuring the distribution to other doping control laboratories. Improving the knowledge of steroid biotransformation is a further benefit from these studies. Characterization of 17-Methylstenbolone and 17-Methylmethenolone and Identification of Metabolites Produced by Human Hepatocytes and Liver Fractions WADA Project no. 11A16CA Christiane Ayotte, Philippe Räss, Alexandre Sylvestre, INRS-Institut Armand-Frappier Summary We have synthesized and characterized two designer steroids, 17α-methylmethenolone and 17α- methylstenbolone; the latter is proposed on the internet and two groups have reported different and contradictory results.
    [Show full text]
  • (200731) Hypromellose Phthalate (220824) Ibudilast
    21222122 Infrared Reference Spectra JP XVII Hypromellose Phthalate (200731) Hypromellose Phthalate (220824) Ibudilast The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21232123 Ibuprofen Ibuprofen Piconol Ifenprodil Tartrate The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21242124 Infrared Reference Spectra JP XVII Imidapril Hydrochloride Imipenem Hydrate Indapamide The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21252125 Indenolol Hydrochloride Indometacin Iohexol The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21262126 Infrared Reference Spectra JP XVII Iopamidol Iotalamic Acid Iotroxic Acid The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia.
    [Show full text]
  • Vargas KEA, Et Al. Hepatotoxicity Associated with Methylstenbolone and Copyright© Vargas KEA, Et Al
    1. Medical Journal of Clinical Trials & Case Studies ISSN: 2578-4838 Hepatotoxicity Associated with Methylstenbolone and Stanozolol Abuse Vargas KEA*, Guaraná TA, Biccas BN, Agoglia LV, Carvalho ACG, Case Report Gismondi R and Esberard EBC Volume 2 Issue 5 Received Date: July 27, 2018 Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Published Date: September 03, 2018 Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense DOI: 10.23880/mjccs-16000176 University, Rio de Janeiro, Brazil *Corresponding author: Vargas Karen Elizabeth Arce, Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense University, Rio de Janeiro, Ernani do Amaral Peixoto Avenue, 935. Ap.901 / Cep.24020043, Brazil, Tel: 005521981584624; Email: [email protected] Abstract Background & Objectives: Drug hepatotoxicity is a major cause of liver disease. Many drugs are well known to induce liver damage. Some toxic products, like anabolic androgenic steroids, that are pharmaceutical preparations since they contain pharmaceutically active substance, are available as nutritional supplements. Many patients are used to consume these like dietary stuff. Methods: We introduce a case series of two patients who developed hepatic damage after the consumption of anabolic- androgenic steroids, accompanied by a detailed bibliographic research on this topic. Results: We present two young men who developed significant liver damage, both with hyperbilirubinemia pattern after consumption of anabolic-androgenic steroids. This was associated with considerable morbidity, although both recovered without liver transplantation. The two anabolic-androgenic steroids were being marketed as dietary supplements. Conclusions: Although not well controlled substances in Brazil, anabolic-androgenic steroids are cause of severe hepatotoxicity.
    [Show full text]
  • Records of Pharmaceutical and Biomedical Sciences
    REVIEW ARTICLE RECORDS OF PHARMACEUTICAL AND BIOMEDICAL SCIENCES Effect of Exogenous Anabolic Androgenic Steroids on Testosterone/ Epitestosterone Ratio and its Application on Athlete Biological Passport in Egypt Hanem A. Khalil a, Dina M. Abo-Elmatty b, Rosa V. Alemany c, Noha M. Mesbah b a Egyptian Anti-Doping Organization, Cairo, Egypt. b Faculty of Pharmacy, Department of Biochemistry Suez Canal University, Ismailia, Egypt. C Catalonian Anti-Doping Laboratory of Fundacio IMIM, Barcelona, Spain. Abstract Received on: 01.09. 2018 Using the Anabolic Androgenic Steroid (AAS) agents is evident not only Revised on: 21. 10. 2018 within the competitive senior and junior athletes, but also in non-sporting contexts by individuals seeking to „improve‟ their physique. No accurate data Accepted on: 01. 11. 2018 is available for the prevalence of AAS misuse among athletes. Studies suggest that it may be 1–5% of the population; with the prevalence being higher in males. Many studies documented side effects and health hazards with the misuse of anabolic steroids, where these were accused as a cause of Correspondence Author: deaths among athletes. Intake of exogenous anabolic steroids disturbed the Testosterone / Epitestosterone (T/E) ratio causing its evaluation above the Tel:+201270206648. normal level. This review outlines the anabolic steroids, its side effects and E-mail address: health impacts in both the sporting and physique development contexts. It also provides a brief review of the history of AAS as doping agents and [email protected] athlete biological passport. Conclusion: Doping among athletes is a widespread public health and social problem. Many studies have shown that both short- and long-term health complications have consequences and dependencies.
    [Show full text]
  • 159 Misuse of Drugs (Controlled Drugs) Order 2001
    MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 BR 37/2001 MISUSE OF DRUGS ACT 1972 1972 : 159 MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 The Minister of Health and Family Services, in exercise of the powers conferred on him by section 3(2) of the Misuse Of Drugs Act 1972, makes the following Order: Citation 1 This Order may be cited as the Misuse Of Drugs (Controlled Drugs) Order 2001. Amendment of Schedule 2 to Act No. 159 of 1972 2 Part I of Schedule 2 to the Misuse of Drugs Act 1972 is deleted and the new Part I set forth in the Schedule to this Order is substituted. Commencement 3 This Order commences on 1st August, 2001. SCHEDULE 2 (paragraph 2) PART I 1. The following substances and products, namely:- (a) ACETORPHINE ACETYLDIHYDROCODEINE ALFENTANIL ALLYLPRODINE ALPHACETYLMETHADOL 1989 Revision 1 MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 ALPHAMEPRODINE ALPHAMETHADOL ALPHAPRODINE ALPRAZOLAM AMPHETAMINE ANILERIDINE ATAMESTANE BENZETHIDINE BENZPHETAMINE BENZYLMORPHINE (3-Benzylmorphine) BETACETYLMETHADOL BETAMEPRODINE BETAMETHADOL BETAPRODINE BEZITRAMIDE BOLANDIOL BOLASTERONE BOLAZINE BOLDENONE BOLENOL BOLMANTALATE BROMAZEPAM BUFOTENINE BUPRENORPHINE CALUUSTERONE CAMAZEPAM CANNABINOL DERIVATIVES CANNABINOL except where contained in Cannabis or Cannabis resin CANNABIS AND CANNABIS RESIN CARFENTANIL CATHINE CATHINONE CHLORDIAZEPOXIDE CHLORPHENTERMINE 4-CHLOROMETHANDIENONE CHORIONIC GONADOTROPHIN (HCG) and NON-HUMAN CHORIONIC GONADOTROPHIN CLENBUTEROL CLOBAZAM CLONAZEPAM CLONITAZENE CLORAZEPIC ACID CLOSTEBOL 2 1989 Revision MISUSE
    [Show full text]
  • Final Report of the Ibu External Review Commission
    IBU External Review Commission Final Report Redacted version FINAL REPORT OF THE IBU EXTERNAL REVIEW COMMISSION REDACTED VERSION 28 January 2021 IBU External Review Commission Final Report Redacted version Table of Contents 1. EXECUTIVE SUMMARY ........................................................................................................ 1 1A. Introduction ............................................................................................................. 1 1B. Cases to answer for breach of the IBU's rules .............................................. 2 1C. Recommendations for action going forward ............................................... 9 1D. Conclusion.............................................................................................................. 11 2. GLOSSARY AND DRAMATIS PERSONAE ....................................................................... 12 2A. Glossary of acronyms ......................................................................................... 12 2B. Key dramatis personae ...................................................................................... 13 3. THE COMMISSION'S FIRST MANDATE: ASSISTING WADA AND THE CRIMINAL AUTHORITIES IN THEIR RESPECTIVE INVESTIGATIONS ..................................... 15 3A. Cooperation with WADA ................................................................................... 15 3B. Cooperation with the criminal authorities ................................................ 15 4. THE COMMISSION'S SECOND MANDATE: UPDATING AND
    [Show full text]
  • Blackstone Indictment
    Case 9:19-cr-80030-WPD Document 1 Entered on FLSD Docket 03/08/2019 Page 1 of 39 M\~ 0 7 2019 ANGELA E. NOBLE UNITED STATES DISTRICT COURT CLERK U.S. DIST CT. S i) OF FLA. - MiAMi SOUTHERN DISTRICT OF FLORIDA 19-80030-CR-DIMITROULEAS/MATTHEWMAN Case No. ------------- 18 u.s.c. § 371 21 U.S.C. §§ 33l(d), 355(a), 333(a)(2) 21 u.s.c. § 846 21 u.s.c. § 841 18 u.s.c. § 1957 18 u.s.c. §§ 981, 982 21 u.s.c. § 853 UNITED STATES OF AMERICA vs. PHILLIP BRAUN, a/k/a "PJ," AARON SINGERMAN, ROBERT DIMAGGIO, ANTHONY VENTRELLA, a/k/a "Joey," JAMES BOCCUZZI, DAVID WINSAUER, BLACKSTONE LABS, LLC, and VENTECH LABS, LLC, Defendants. ______________/ INDICTMENT The Grand Jury charges that: GENERAL ALLEGATIONS At all times relevant to this Indictment: Food, Drugs, and Dietary Supplements Under the Food, Drug, and Cosmetic Act 1. The Food and Drug Administration (FDA) was the agency of the United States responsible for, among other things, enforcing the provisions of the Federal Food, Drug, and Case 9:19-cr-80030-WPD Document 1 Entered on FLSD Docket 03/08/2019 Page 2 of 39 Cosmetic Act (FDCA), 21 U.S.C. § 301 et seq. FDA's primary purpose in enforcing the FDCA was to protect the health and safety of consumers in the United States. FDA's responsibilities included regulating the manufacturing, labeling, and distribution of food and drugs shipped or received in interstate commerce. FDA's responsibilities included preventing improperly packaged or labeled food and drugs not approved for sale from reaching consumers.
    [Show full text]
  • Reproductive DHEA
    Reproductive DHEA Analyte Information - 1 - DHEA Introduction DHEA (dehydroepiandrosterone), together with other important steroid hormones such as testosterone, DHT (dihydrotestosterone) and androstenedione, belongs to the group of androgens. Androgens are a group of C19 steroids that stimulate or control the development and maintenance of male characteristics. This includes the activity of the male sex organs and the development of secondary sex characteristics. Androgens are also precursors of all estrogens, the female sex hormones. DHEA (dehydroepiandrosterone) is the aromatic C19-steroid composed of a 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one, its summary formula is C19H28O2, and its molecular weight (Mr) is 288.4 Da. The structural formulas of DHEA and related androgens are shown in Fig.1 Fig.1: Structural formulas of the most important androgens DHEA Androstenedione Testosterone Dihydrotestosterone There are more than 40 other names used for DHEA, including: (+)-Dehydroisoandrosterone; (3beta, 16alpha)-3,16-dihydroxy-androst-5-en- 17-one; 5,6-Dehydroisoandrosterone; 17-Chetovis, 17-Hormoforin, Andrestenol, Diandron, Prasterone and so on. As DHEA is very closely connected with its sulfate form DHEA-S, both hormones are mentioned together in the following text. Biosynthesis DHEA is the steroid hormone belonging to the weak androgens. DHEA and DHEA-S are the major C19 steroids produced from cholesterol by the zona reticularis of the adrenal cortex (Fig.2). DHEA is also produced in small quantities in the gonads (testis and ovary3,8,14), in adipose tissue and in the brain. From this point of view DHEA belongs to the neurosteroids22.
    [Show full text]